URINARY INCONTINENCE TREATMENT DRUGS MARKET ANALYSIS

Market Challenges And Opportunities

Global Urinary Incontinence Treatment Drugs Market– Drivers

• Increasing number of regulatory approval for drugs: Increasing number of regulatory approval for drugs boosts the global urinary incontinence treatment drugs market growth. For instance, in December 2020, Urovant Sciences, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for 75 mg GEMTESA (vibegron), a beta-3 adrenergic receptor (β3) agonist,  once daily for the treatment of overactive bladder (OAB). The symptoms of urge urinary incontinence (UUI) includes  urgency and frequency of urination in adults. This approval marks the first new brand-name oral OAB drug approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences.
•  Increasing prevalence of urinary incontinence: Increasing prevalence of urinary incontinence is expected to boost demand for urinary incontinence treatment drugs, and this is  expecetd to drive the global urinary incontinence treatment drugs market growth. For instance, in September 2021,  according to a research study published by International Journal of Obstetrics and Gynaecology, , 24,985 women (mean age 41.9 years) were considered for the study. The follow-up rate was 55.5%, the mean follow-up time was 3.7 years. The standardized incidences of urinary incontinence (UI), stress urinary incontinence (SUI), urge urinary incontinence (UUI), and mixed urinary incontinence (MUI) were 21.2, 13.1, 3.0, and 5.1 per 1000 person-years, respectively.

Global Urinary Incontinence Treatment Drugs Market: Restraint

• Side effects associated with the drugs: Side effects associated with drug treatment is expected to hinder the market growth over the forecast period. Approved drug such as Myrbetriq may cause side effects such as increased blood pressure, in which Myrbetriq may cause their blood pressure to increase or worsen if they had high blood pressure in the past. Moreover, Myrbetriq may increase the chance that patient will not be able to empty their bladder if they have bladder emptying disorder or if they are taking other medicines to treat overactive bladder.
• Counterbalance: Key players are focusing on developing treatment options with safety and cost effective methods, and this is expected to drive the market growth over the forecast period.